These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 35728123)

  • 1. Contribution of machine learning to tumor growth inhibition modeling for hepatocellular carcinoma patients under Roblitinib (FGF401) drug treatment.
    Wilbaux M; Demanse D; Gu Y; Jullion A; Myers A; Katsanou V; Meille C
    CPT Pharmacometrics Syst Pharmacol; 2022 Aug; 11(8):1122-1134. PubMed ID: 35728123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integration of Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy into Model-Informed Dose Selection in Oncology First-in-Human Study: A Case of Roblitinib (FGF401).
    Wilbaux M; Yang S; Jullion A; Demanse D; Porta DG; Myers A; Meille C; Gu Y
    Clin Pharmacol Ther; 2022 Dec; 112(6):1329-1339. PubMed ID: 36131557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors.
    Chan SL; Schuler M; Kang YK; Yen CJ; Edeline J; Choo SP; Lin CC; Okusaka T; Weiss KH; Macarulla T; Cattan S; Blanc JF; Lee KH; Maur M; Pant S; Kudo M; Assenat E; Zhu AX; Yau T; Lim HY; Bruix J; Geier A; Guillén-Ponce C; Fasolo A; Finn RS; Fan J; Vogel A; Qin S; Riester M; Katsanou V; Chaudhari M; Kakizume T; Gu Y; Porta DG; Myers A; Delord JP
    J Exp Clin Cancer Res; 2022 Jun; 41(1):189. PubMed ID: 35655320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of Roblitinib (FGF401) as a Reversible-Covalent Inhibitor of the Kinase Activity of Fibroblast Growth Factor Receptor 4.
    Fairhurst RA; Knoepfel T; Buschmann N; Leblanc C; Mah R; Todorov M; Nimsgern P; Ripoche S; Niklaus M; Warin N; Luu VH; Madoerin M; Wirth J; Graus-Porta D; Weiss A; Kiffe M; Wartmann M; Kinyamu-Akunda J; Sterker D; Stamm C; Adler F; Buhles A; Schadt H; Couttet P; Blank J; Galuba I; Trappe J; Voshol J; Ostermann N; Zou C; Berghausen J; Del Rio Espinola A; Jahnke W; Furet P
    J Med Chem; 2020 Nov; 63(21):12542-12573. PubMed ID: 32930584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FGF401 and vinorelbine synergistically mediate antitumor activity and vascular normalization in FGF19-dependent hepatocellular carcinoma.
    Huynh H; Prawira A; Le TBU; Vu TC; Hao HX; Huang A; Wang Y; Porta DG
    Exp Mol Med; 2020 Nov; 52(11):1857-1868. PubMed ID: 33235319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bile Acid Sequestration by Cholestyramine Mitigates FGFR4 Inhibition-Induced ALT Elevation.
    Schadt HS; Wolf A; Mahl JA; Wuersch K; Couttet P; Schwald M; Fischer A; Lienard M; Emotte C; Teng CH; Skuba E; Richardson TA; Manenti L; Weiss A; Graus Porta D; Fairhurst RA; Kullak-Ublick GA; Chibout SD; Pognan F; Kluwe W; Kinyamu-Akunda J
    Toxicol Sci; 2018 May; 163(1):265-278. PubMed ID: 29432567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamic Modeling of CDK4/6 Inhibition-Related Biomarkers and the Characterization of the Relationship Between Biomarker Response and Progression-Free Survival in Patients With Advanced Breast Cancer.
    Yu Y; Sun W; Liu Y; Wang D
    J Clin Pharmacol; 2022 Mar; 62(3):376-384. PubMed ID: 34554584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted inhibition of FGF19/FGFR cascade improves antitumor immunity and response rate in hepatocellular carcinoma.
    Tai DWM; Le TBU; Prawira A; Ho RZW; Huynh H
    Hepatol Int; 2021 Oct; 15(5):1236-1246. PubMed ID: 34333737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetic analysis of sorafenib in patients with solid tumours.
    Jain L; Woo S; Gardner ER; Dahut WL; Kohn EC; Kummar S; Mould DR; Giaccone G; Yarchoan R; Venitz J; Figg WD
    Br J Clin Pharmacol; 2011 Aug; 72(2):294-305. PubMed ID: 21392074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer.
    Weiss A; Adler F; Buhles A; Stamm C; Fairhurst RA; Kiffe M; Sterker D; Centeleghe M; Wartmann M; Kinyamu-Akunda J; Schadt HS; Couttet P; Wolf A; Wang Y; Barzaghi-Rinaudo P; Murakami M; Kauffmann A; Knoepfel T; Buschmann N; Leblanc C; Mah R; Furet P; Blank J; Hofmann F; Sellers WR; Graus Porta D
    Mol Cancer Ther; 2019 Dec; 18(12):2194-2206. PubMed ID: 31409633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of FGF401 as a reversible covalent inhibitor of fibroblast growth factor receptor 4.
    Zhou Z; Chen X; Fu Y; Zhang Y; Dai S; Li J; Chen L; Xu G; Chen Z; Chen Y
    Chem Commun (Camb); 2019 May; 55(42):5890-5893. PubMed ID: 31041948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel semi-mechanistic tumor growth fraction model for translation of preclinical efficacy of anti-glypican 3 antibody drug conjugate to human.
    Singh R; Kozhich A; Pan C; Lee F; Cardarelli P; Vangipuram R; Iyer R; Marathe P
    Biopharm Drug Dispos; 2020 Nov; 41(8-9):319-333. PubMed ID: 32678919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584.
    Liu Y; Poon RT; Li Q; Kok TW; Lau C; Fan ST
    Cancer Res; 2005 May; 65(9):3691-9. PubMed ID: 15867364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma.
    Bollard J; Miguela V; Ruiz de Galarreta M; Venkatesh A; Bian CB; Roberto MP; Tovar V; Sia D; Molina-Sánchez P; Nguyen CB; Nakagawa S; Llovet JM; Hoshida Y; Lujambio A
    Gut; 2017 Jul; 66(7):1286-1296. PubMed ID: 27849562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical pharmacokinetics, disposition, and translational pharmacokinetic/pharmacodynamic modeling of savolitinib, a novel selective cMet inhibitor.
    Gu Y; Sai Y; Wang J; Yu M; Wang G; Zhang L; Ren H; Fan S; Ren Y; Qing W; Su W
    Eur J Pharm Sci; 2019 Aug; 136():104938. PubMed ID: 31132401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pyrrolo[2,3-b]pyridine-3-one derivatives as novel fibroblast growth factor receptor 4 inhibitors for the treatment of hepatocellular carcinoma.
    Jin Q; Zhang D; Gao M; Jiang C; Zhang J
    Bioorg Med Chem; 2021 Jan; 29():115862. PubMed ID: 33218898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiscale systems pharmacological analysis of everolimus action in hepatocellular carcinoma.
    Ande A; Chaar M; Ait-Oudhia S
    J Pharmacokinet Pharmacodyn; 2018 Aug; 45(4):607-620. PubMed ID: 29725796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cabozantinib exposure-response analyses of efficacy and safety in patients with advanced hepatocellular carcinoma.
    Nguyen L; Chapel S; Tran BD; Lacy S
    J Pharmacokinet Pharmacodyn; 2019 Dec; 46(6):577-589. PubMed ID: 31637577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apatinib prevents natural killer cell dysfunction to enhance the efficacy of anti-PD-1 immunotherapy in hepatocellular carcinoma.
    Yang Y; Wang C; Sun H; Jiang Z; Zhang Y; Pan Z
    Cancer Gene Ther; 2021 Feb; 28(1-2):89-97. PubMed ID: 32533100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic-Pharmacodynamic-Efficacy Modeling of ONO-7579, a Novel Pan-Tropomyosin Receptor Kinase Inhibitor, in a Murine Xenograft Tumor Model.
    Iida H; Fujikawa R; Kozaki R; Harada R; Hosokawa Y; Ogawara KI; Ohno T
    J Pharmacol Exp Ther; 2020 Jun; 373(3):361-369. PubMed ID: 32217770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.